Rocket Science Health has reported a new milestone in intranasal drug delivery after a non-human primate study showed its device technology successfully targeted the olfactory cleft, a region seen as a potential route for direct-to-brain administration. The company said the findings strengthen the case for using intranasal approaches to deliver vaccines and therapeutics that must bypass traditional barriers such as the blood-brain barrier.
Targeted deposition confirmed across all nostrils tested
According to the report, the evaluation was carried out in collaboration with ClearPoint Neuro at ClearPoint Advanced Laboratories. Three rhesus macaques completed two sedated sessions each, producing 12 nostril-session samples. The study assessed anatomical fit, repeatable placement and targeted deposition of a low-viscosity water-like tracer by endoscopic imaging.
The company said deposition to the targeted olfactory region was confirmed in all nostrils tested. It also reported consistent and repeatable device placement, no insertion resistance across study days, and no nasopharyngeal drainage or backflow out of the nose at the assessment time points.
No device-related adverse events were observed
Rocket Science Health said no device-related adverse events or observable acute nasal trauma were noted during fitting, placement or delivery. The company described its technology as being built around human factors, vantage point and fluidics, with configurability across drug volumes and viscosities.
The firm also said it holds U.S. patent protection spanning both fluidics design and targeted delivery methods, supporting a combination-product commercialization pathway. The results were presented as aligning with the focus of the upcoming 4th Nasal Formulation & Delivery Summit in Boston, where intranasal therapies and device selection are expected to be central topics.
For developers working on CNS and brain-related treatments, the findings add to growing interest in delivery systems that can improve precision while remaining non-invasive. Rocket Science Health said the data provide a bridge toward human commercialization, though the study itself was limited to non-human primates and assessed tracer visibility only up to 10 minutes after delivery.
The report adds another example of how delivery technology is becoming as important as the molecule itself in modern drug development, particularly in areas where targeted administration may influence both efficacy and patient experience.
Source: News-Medical report
